Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05829291 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Feb 2025 to Feb 2027
    • Study completion date: Feb 2026 to Jul 2027
    • Study title revised
    v5
  2. Study description expanded, about 34 wordsv4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Oct 2023 to Oct 1, 2023
    v3
  4. Start date: May 2023 to Oct 2023v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single center study enrolling up to 10 patients. The primary objective is to Evaluate the feasibility and safety of the DaRT for the treatment of Liver Metastases. The secondary objective is to evaluate the pathological response of liver metastases according to the Modified tumor regression grade\[1\] and to evaluate the radiological response of liver metastases using the RECIST criteria.
Trial Details
NCT Number NCT05829291
Lead Sponsor Alpha Tau Medical LTD.
Conditions
(from sponsor)		 Liver Metastases
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov